Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Depreciation & Amortization (CF) (2021 - 2025)

Kezar Life Sciences' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $227000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 12.69% year-over-year to $227000.0; the TTM value through Sep 2025 reached $980000.0, down 7.63%, while the annual FY2024 figure was $1.0 million, 2.44% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $227000.0 at Kezar Life Sciences, down from $243000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $458000.0 in Q3 2022 and bottomed at -$283000.0 in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $261000.0 (2024), against an average of $282105.3.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 173.13% in 2022 before it soared 198.94% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $387000.0 in 2021, then crashed by 173.13% to -$283000.0 in 2022, then skyrocketed by 198.94% to $280000.0 in 2023, then dropped by 7.5% to $259000.0 in 2024, then decreased by 12.36% to $227000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Depreciation & Amortization (CF) are $227000.0 (Q3 2025), $243000.0 (Q2 2025), and $251000.0 (Q1 2025).